OracleBio contributed to a Pre-clinical R&D program for a UK-based drug discovery company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.
By utilising Immunohistochemistry (IHC) and quantitative digital pathology, we supported the data-driven decision-making process for proof of mechanism studies by providing quantitative and reproducible tissue-based evidence for the mechanism of action of an anti-CTLA4 checkpoint inhibitor treatment associated with change in tumour volume and %CD8 staining.
Click here to view the Case Study poster and learn more about the aim and outcome.
To find out more about OracleBio’s digital pathology services to support Immuno-oncology R&D, please click here.
To keep up to date with all OracleBio news and publications, please follow us on LinkedIn by clicking the button below: